Natera

Oncology Pathology Assistant

United States

Natera Logo
Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, Medical LaboratoryIndustries

Requirements

Candidates must possess a Bachelor’s degree, or higher, with certification by the American Society of Clinical Pathology (ASCP), or equivalent board. A minimum of 10 years of experience in anatomic pathology, including extensive knowledge of solid tumor pathology, is required.

Responsibilities

The Oncology Pathology Assistant will assist the Signatera team as a subject matter expert for review of clinical pathology reports and clinical notes, interpret oncology pathology reports to identify optimal samples to request, read and ensure accurate curation of clinical history and specimen information, devise strategies for data retrieval, maintain proficiency with diagnostic data according to WHO guidelines, serve as a subject matter expert for various teams, assist in identifying suboptimal sample collection times, provide support for clinical trials, and perform other duties as assigned.

Skills

Pathology
Anatomic Pathology
Solid Tumor Pathology
Clinical Pathology Reports
Specimen Acquisition
Database Management
WHO Guidelines
Sample Curation
Data Stratification
Laboratory Procedures
Clinical Trial Support

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Key Metrics

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI